The trial, MM-002, was a randomized open-label Phase II study evaluating pomalidomide plus low-dose dexamethasone versus pomalidomide alone in relapsed and refractory multiple myeloma patients. Pomalidomide, with or without low-dose dexamethasone, was given in 28-day cycles: pomalidomide 4 mg once daily on days 1-21 every 28 days, and low-dose dexamethasone (40 mg) weekly.
Results presented were based on investigator-assessed responses for the intent-to-treat population. A total of 221 patients were enrolled in the study, and 191 patients were available for response. The study showed that out of 191 evaluable patients, partial response (PR) or better was seen in 34% of patients treated with pomalidomide plus low-dose dexamethasone compared with 13% of patients treated with pomalidomide alone.
Objective responses (minor response or better) were observed in 45% of patients treated with pomalidomide plus low-dose dexamethasone compared with 29% in the pomalidomide-only arm. Median progression-free survival, the primary end point of the study, was 4.7 months in the pomalidomide plus low-dose dexamethasone arm compared with 2.7 months in the pomalidomide-alone arm. Median duration of response (DOR) was 7.9 months in the pomalidomide plus low-dose dexamethasone arm compared with 8.5 months with pomalidomide alone, and median overall survival was 16.9 months compared with 14 months, respectively. Similar results were observed in all subsets of patients, including patients refractory to lenalidomide and patients refractory to both lenalidomide and bortezomib. Results from the independent adjudication were similar.
Patients in both arms of the study had been heavily treated prior to enrollment, with a median of 5 (range, 2 to 13) prior therapies. More than 74% and 76% of patients in the pomalidomide plus low-dose dexamethasone arm and pomalidomide alone arm, respectively, had undergone autologous stem cell transplantation.
Discontinuation rate due to adverse events was 6% in the pomalidomide plus low-dose dexamethasone arm, compared with 12% in the pomalidomide alone arm. The most common grade 3 or 4 adverse events in the pomalidomide plus low-dose dexamethasone arm versus pomalidomide alone were neutropenia (38% and 45%, respectively), anemia (21%, 17%), pneumonia (19%, 8%), thrombocytopenia (19%, 21%), and fatigue (10%, 8%).
These data are from an investigational study. Pomalidomide is not an approved product for any indication.
About Multiple Myeloma
Multiple myeloma (also known as myeloma or plasma cell myeloma) is a cancer of the blood in which malignant plasma cells are overproduced in the bone marrow. Plasma cells are white blood cells that help produce antibodies called immunoglobulins that fight infection and disease. However, most patients with multiple myeloma have cells that produce a form of immunoglobulin called paraprotein (or M protein) that does not benefit the body. In addition, the malignant plasma cells replace normal plasma cells and other white blood cells important to the immune system. Multiple myeloma cells can also attach to other tissues of the body, such as bone, and produce tumors. The cause of the disease remains unknown.
About Celgene International Sàrl
Celgene International Sàrl, located in Boudry, in the
This press release contains forward-looking statements, which are
generally statements that are not historical facts. Forward-looking
statements can be identified by the words "expects," "anticipates,"
"believes," "intends," "estimates," "plans," "will," “outlook” and
similar expressions. Forward-looking statements are based on
management’s current plans, estimates, assumptions and projections, and
speak only as of the date they are made. We undertake no obligation to
update any forward-looking statement in light of new information or
future events, except as otherwise required by law. Forward-looking
statements involve inherent risks and uncertainties, most of which are
difficult to predict and are generally beyond our control. Actual
results or outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
factors, many of which are discussed in more detail in our Annual Report
on Form 10-K and our other reports filed with the
Source: Celgene International Sàrl